What did perioperative camrelizumab trials show?

Perioperative immunotherapy improves outcomes for resectable liver cancer

For patients with resectable hepatocellular carcinoma, a perioperative approach using immunotherapy around the time of surgery has shown a meaningful survival benefit in a large clinical trial. In the CARES-009 study, researchers compared perioperative camrelizumab plus rivoceranib against surgery alone.

The key outcome reported was event-free survival, and the combination significantly improved it. That matters clinically because “event-free” endpoints typically capture both recurrence and other disease-related events after treatment, providing an earlier signal of whether the additional therapy is helping keep cancer controlled after surgery.

What this changes for practice

Historically, surgery has been central for resectable hepatocellular carcinoma, but recurrence remains a major challenge. Adding systemic therapy in the perioperative period aims to treat microscopic disease that surgery may not eliminate and to reduce the risk that cancer returns.

The trial framing—immunotherapy combined with targeted therapy given around the operation—reflects an emerging strategy: using disease-control tools at the moment the tumor burden is lowest to improve long-term outcomes.

The uncertainty that remains

While trial results support the effectiveness of the combined regimen, the record provided also includes responses and discussion from authors (letters) about differences or discrepancies in interpretation. That suggests some scientific debate about how results are compared or characterized, though specific points and final resolution weren’t included in the excerpt.

Still, the headline takeaway from CARES-009 is straightforward: perioperative camrelizumab plus rivoceranib improves event-free survival versus surgery alone in resectable hepatocellular carcinoma, strengthening the evidence for perioperative systemic therapy in this setting.